EBS
NYSE · Biotechnology
Emergent Biosolutions Inc
$7.22
-0.04 (-0.55%)
Financial Highlights (FY 2026)
Revenue
501.79M
Net Income
35.53M
Gross Margin
56.1%
Profit Margin
7.1%
Rev Growth
-12.8%
D/E Ratio
1.09
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 56.1% | 56.1% | 45.0% | 45.0% |
| Operating Margin | 11.8% | 10.6% | -22.1% | -20.0% |
| Profit Margin | 7.1% | 6.7% | -22.5% | -19.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 501.79M | 575.51M | 356.03M | 320.59M |
| Gross Profit | 281.45M | 322.80M | 160.06M | 144.13M |
| Operating Income | 59.36M | 61.27M | -78,668,458 | -64,121,079 |
| Net Income | 35.53M | 36.67M | -80,261,545 | -61,575,433 |
| Gross Margin | 56.1% | 56.1% | 45.0% | 45.0% |
| Operating Margin | 11.8% | 10.6% | -22.1% | -20.0% |
| Profit Margin | 7.1% | 6.7% | -22.5% | -19.2% |
| Rev Growth | -12.8% | -12.8% | +7.9% | +14.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 72.25M | 72.25M | 108.79M | 90.00M |
| Total Equity | 66.00M | 66.00M | 281.81M | 307.34M |
| D/E Ratio | 1.09 | 1.09 | 0.39 | 0.29 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 103.34M | 112.60M | -95,339,299 | -103,196,575 |
| Free Cash Flow | — | — | -67,766,487 | -48,928,891 |